Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2022

Filing Date
Filed February 9, 2023
Period End
December 31, 2022
Security
NBIX
One revenue dollarkept$0.10
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 9, 2023. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported 2022 total revenues of $1,488.7 milliona, up from $1,133.5 million in 2021, and net income of $154.5 million, compared with $89.6 million in 2021.

Product sales are driven almost entirely by INGREZZA, which had net product sales of $1,427.8 millionb in 2022, an increase of $345.9 million, or 32.0%, attributed to increased new patient starts, higher prescriptions, and continued investment in a direct-to-consumer advertising campaign and an expanded sales force. Operating income was $249.0 million, but research and development expense rose to $463.8 million from $328.1 million and selling, general and administrative expense rose to $752.7 million from $583.3 million. Diluted earnings per share were $1.56, compared with $0.92 in 2021.

The balance sheet strengthened in liquidity while debt was reduced. Cash, cash equivalents and marketable securities totaled $1,288.7 millionc at December 31, 2022. The company repurchased $210.8 million of its 2.25% convertible senior notes due 2024 for $279.0 million in cash, recognizing a $70.0 million loss on extinguishment, leaving $170.4 million outstanding.

Management states that existing capital resources and anticipated revenues are sufficient to meet funding requirements for at least the next 12 months. The company also reported an accumulated deficit of $406.8 milliond and operating cash flow of $339.4 million for 2022. The filing highlights concentration and legal risk.

Four customers represented approximately 89% of total product revenue for 2022 and approximately 95% of accounts receivable at December 31, 2022. Several generic applicants have filed ANDAs against INGREZZA, and the company's patent suits are consolidated in the District of Delaware with trial scheduled for January 2, 2024. Pipeline catalysts include an FDA target action date of August 20, 2023 for valbenazine in chorea associated with Huntington disease, and top-line data expected in the second half of 2023 for crinecerfont in congenital adrenal hyperplasia.

Key Highlights

  1. Total revenues of $1,488.7 million in 2022, versus $1,133.5 million in 2021; net income of $154.5 million, versus $89.6 million.
  2. INGREZZA net product sales of $1,427.8 million in 2022, an increase of $345.9 million, or 32.0%, driven by new patient starts and higher prescriptions.
  3. Cash, cash equivalents and marketable securities of $1,288.7 million at December 31, 2022, and operating cash flow of $339.4 million for 2022.
  4. Repurchased $210.8 million of 2024 convertible notes for $279.0 million in cash, incurring a $70.0 million loss on extinguishment; $170.4 million principal remains outstanding.
  5. Acquired Diurnal Group plc in November 2022 for $55.2 million in cash, and agreed on January 8, 2023 to pay Voyager Therapeutics $175 million upfront, including a $39 million equity investment.
  6. Customer concentration: four customers represented approximately 89% of total product revenue and approximately 95% of accounts receivable at December 31, 2022.
  7. Pipeline: FDA accepted the sNDA for valbenazine in Huntington disease chorea with a PDUFA target date of August 20, 2023; a second Phase III schizophrenia study began in December 2022.

Follow one dollar

Of each $1.00 of revenue in FY2022, Neurocrine Biosciences kept $0.10.

  1. Revenue$1.49B100.0%
  2. Cost of revenue−$23.2M1.6%
  3. Gross profit$1.47B98.4%
  4. Operating costs−$1.22B81.7%
  5. Operating income$249.0M16.7%
  6. Interest, other & tax−$94.5M6.3%
  7. Net income$154.5M10.4%
Computed from 10-KFY2022filed February 9, 2023Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2022 revenue went

$1.49B
  • SG&A: $752.7M, 51% of revenue
  • Other operating costs: $463.8M, 31% of revenue
  • Net income: $154.5M, 10% of revenue
  • Cost of revenue: $23.2M, 1.6% of revenue
  • Interest, other & tax: $94.5M, 6.3% of revenue

Kept 10% as net income

Full revenue history →

Financial Statements

FY2022 against FY2021

Line itemFY2022FY2021Change
Revenue$1.49B$1.13B+31.3%
Cost of Revenue$23.20M$14.30M+62.2%
Gross Profit$1.47B$1.12B+30.9%
SG&A Expenses$752.70M$583.30M+29.0%
Operating Expenses$1.24B$1.03B+20.2%
Operating Income$249.00M$102.50M+142.9%
Interest Expense$7.10M$25.80M−72.5%
Net Income$154.50M$89.60M+72.4%
EPS (Basic)$1.61$0.95+69.5%
EPS (Diluted)$1.56$0.92+69.6%
Shares Outstanding (Basic)95.80M94.60M+1.3%
Shares Outstanding (Diluted)98.90M97.90M+1.0%

Frequently Asked Questions

  1. What drove revenue growth in 2022?

    Total product sales rose to $1,440.9 million from $1,090.1 million, primarily reflecting INGREZZA net product sales, which increased $345.9 million, or 32.0%, to $1,427.8 million. The company attributes this to increased new patient starts, higher total prescriptions, and increased commercial activities, including its direct-to-consumer advertising campaign launched in May 2021 and its sales force expansion completed in April 2022. Collaboration revenue was $47.8 million, including a $20.0 million milestone tied to MTPC's first commercial sale of DYSVAL in Japan.

  2. How did operating expenses change, and what drove profitability?

    Research and development expense increased to $463.8 million from $328.1 million, and selling, general and administrative expense increased to $752.7 million from $583.3 million. Acquired in-process R&D was zero in 2022, compared with $105.3 million in 2021. Operating income was $249.0 million. Net income also benefited from lower interest expense of $7.1 million, although total other expense, net, was $35.1 million, including the $70.0 million debt extinguishment loss. The income tax provision was $59.4 million.

  3. What is the company's debt position and liquidity outlook?

    Total debt outstanding decreased by $210.8 million to $170.4 million after the second-quarter 2022 repurchase, which the company says represented approximately 55% of total debt outstanding. The 2024 Notes became convertible during the first quarter of 2023 because the conditional conversion feature was triggered, and the company is required to settle principal in cash. Management believes existing capital resources and anticipated revenues will be sufficient to satisfy funding requirements for at least the next 12 months.

  4. What are the main risks identified in the filing?

    Key risks include dependence on INGREZZA for nearly all product sales, reliance on a limited number of customers and third-party manufacturers, and pricing and reimbursement pressure, including the Inflation Reduction Act of 2022. The filing also cites competition from AUSTEDO and generics, litigation over generic applications against INGREZZA, potential changes to tax treatment of research and development expenses that the company expects would materially decrease its operating cash flows over the amortization period, and the company's history of losses, with an accumulated deficit of $406.8 million.

  5. What near-term catalysts and legal milestones are disclosed?

    The FDA set a PDUFA target action date of August 20, 2023 for valbenazine in chorea associated with Huntington disease. Top-line data are expected in the second half of 2023 for crinecerfont in adult and pediatric congenital adrenal hyperplasia, and in the second half of 2023 for NBI-921352 in focal onset seizures and NBI-1065846 in anhedonia. In the patent litigation against several generic applicants, the consolidated Delaware trial is scheduled for January 2, 2024.